The ORAI Calcium Release Activated Calcium Modulator pipeline drugs market research report outlays comprehensive information on the ORAI Calcium Release Activated Calcium Modulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ORAI Calcium Release Activated Calcium Modulator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Central Nervous System, Infectious Disease, and Oncology which include the indications Pancreatitis, Ulcerative Colitis, Alzheimer’s Disease, Multiple Sclerosis, Unspecified Viral Infections, Sepsis, Breast Cancer, and Ovarian Cancer. It also reviews key players involved in ORAI Calcium Release Activated Calcium Modulator targeted therapeutics development with respective active and dormant or discontinued products.
The ORAI Calcium Release Activated Calcium Modulator pipeline targets constitutes close to 17 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 8, and 6 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
ORAI Calcium Release Activated Calcium Modulator overview
ORAI calcium release activated calcium modulator (ORAI) is a membrane calcium channel subunit that is activated by the calcium sensor STIM1 when calcium stores are depleted. This type of channel is the primary way for calcium influx into T-cells. Defects in this gene are a cause of immune dysfunction with T-cell inactivation due to calcium entry defect.
For a complete picture of ORAI Calcium Release Activated Calcium Modulator’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
